Drugs / MVC-COV1901
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05216601 | May → Jul 2022 | — | Medigen Vaccine Biologics Corp. | Completed | No outcome recorded |
| Phase 1 | NCT04487210 | Oct 2020 → Jun 2021 | COVID-19 | Medigen Vaccine Biologics Corp. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05132855 | Nov 2021 → Apr 2023 | COVID-19 | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 27 trials · 1 met primary | ||||||
| Phase 2 | NCT05197153 | Jan → Jun 2022 | — | Medigen Vaccine Biologics Corp. | Completed | No outcome recorded |
| Phase 2 | NCT05054621 | Sep 2021 → Aug 2022 | COVID-19 | Chang Gung Memorial Hospital | Completed | Met primary |
| Phase 2 | NCT05038618 | Aug → Oct 2021 | — | Medigen Vaccine Biologics Corp. | Completed | No outcome recorded |
| Phase 2 | NCT04951388 | Jul → Oct 2021 | — | Medigen Vaccine Biologics Corp. | Completed | No outcome recorded |
| Phase 2 | NCT05048849 | Jul → Nov 2021 | — | Medigen Vaccine Biologics Corp. | Completed | No outcome recorded |
| Phase 2 | NCT04822025 | May → Aug 2021 | — | Medigen Vaccine Biologics Corp. | Completed | No outcome recorded |
| Phase 2 | NCT04695652 | Dec 2020 → May 2021 | — | Medigen Vaccine Biologics Corp. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05198596 | Jul → Nov 2022 | — | Medigen Vaccine Biologics Corp. | Completed | No outcome recorded |
| Phase 3 | NCT05426343 | Jul → Oct 2022 | — | Medigen Vaccine Biologics Corp. | Completed | No outcome recorded |
| Phase 3 | NCT05011526 | Oct → Dec 2021 | — | Medigen Vaccine Biologics Corp. | Completed | No outcome recorded |
| Phase 42 trials · 1 missed | ||||||
| Phase 4 | NCT05097053 | Oct 2021 → Mar 2022 | — | Taoyuan General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05079633 | Sep → Oct 2021 | — | National Taiwan University Hospital | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-09-01 | Medigen Vaccine Biologics Corp. | Results 高端發布次世代新冠疫苗（Beta）一期試驗對流行株BA.4/BA.5之正面數據 medigenvac.com ↗
以次世代（Beta株）作為追加劑，相比原型株效果更好，可顯著提升對武漢株、變異株Beta、Omicron BA.4/BA.5的中和抗體效價。 |
| 2021-03-23 | Medigen Vaccine Biologics Corp. | Results 高端疫苗於MedRxiv刊載MVC-COV1901新冠疫苗對不同病毒變異株的中和抗體效價數據 medigenvac.com ↗
本研究發現：施打MVC-COV1901疫苗後的大鼠對於野生型、歐洲D614G、英國B.1.1.7型、和南非 B.1.351型等4種新冠病毒可產生足夠中和抗體效價，但其中特殊的南非變種病毒之中和抗體效價則略有下降。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-09-01 | Medigen Vaccine Biologics Corp. | 高端發布次世代新冠疫苗（Beta）一期試驗對流行株BA.4/BA.5之正面數據 medigenvac.com ↗ |
| 2021-03-23 | Medigen Vaccine Biologics Corp. | 高端疫苗於MedRxiv刊載MVC-COV1901新冠疫苗對不同病毒變異株的中和抗體效價數據 medigenvac.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVC COV1901 | “MVC-COV1901 is a protein vaccine based on the same SARS-CoV-2 strain used in mRNA vaccine mRNA-1273.” PMID 37321955 ↗ Jun 202315“Medigen COVID-19 vaccine (MVC COV1901)” NCT05079633 ↗ |
| Known as | Medigen COVID-19 vaccine | “Medigen COVID-19 vaccine (MVC COV1901)” NCT05079633 ↗ |
| Modality | Vaccine | “MVC-COV1901 is a protein subunit COVID-19 vaccine” PMID 35579840 ↗ May 2022 |
| Route | Intramuscular | “administered by intramuscular (IM) injection” NCT04487210 ↗ |